LAS VEGAS, October 23, 2017 /PRNewswire/ --
Companies in the biotechnology arena are in business to save lives. Such audacious goals come with lots of risk in the stock market, but if successful, even more reward. In the biotech industry, companies can spend hundreds of millions of dollars and in the end have nothing to show for it. Additionally, Biotech relies on scientific research and data, from this research these companies patent their technologies, and products. A few biotechnology companies to compare and contrast include: Endonovo Therapeutics (OTCQB: ENDV), Pulse Biosciences, Inc. (NASDAQ: PLSE), TherapeuticsMD, Inc. (NASDAQ: TXMD), Genocea Biosciences, Inc. (NASDAQ: GNCA), and Exelixis, Inc. (NASDAQ: EXEL).
Endonovo Therapeutics (OTCQB: ENDV)
Market Cap: $18.244M, current share price: $.059
Just last week, ENDV announced the completion of a study evaluating the effectiveness of its lead platform with positive results. After their success in the completed pre-clinical trial, its apparent ENDV is leading the way in biotechnology and electroceuticals. Their lead platform, Immunotronics™, is a non-invasive electroceutical, and the pre-clinical study measured evaluated it against in a well-established preclinical model of heart failure (post-MI remodeling). This model used Immunotronics™ one, two or three times per day and discovered it drastically increased significantly improved cardiac function and reduced ventricular remodeling, including significant improvements in ejection fraction (EF), fractional shortening (FS) and Left Ventricle Developed Pressure (LVDP), as well as Heart-Weight-to-Body-Weight ratio (HW/BW), which is an index for cardiac hypertrophy (enlarged heart). With its recent success, ENDV plans to continue the development of its pipeline of non-invasive electroceuticals. The completion of this study is a milestone for the electroceutical field and places ENDV as a leader in developing non-invasive therapies for patients with life-threatening inflammatory conditions in vital organs and vascular disease.
Pulse Biosciences, Inc. (NASDAQ: PLSE)
Market Cap: $399.34M, current share price: $24.44
Similar to ENDV's bioelectronics platform, PLSE is developing a therapeutic tissue treatment platform based on Nano-Pulse. Late last month, PLSE announced it has entered into a stock purchase agreement with Robert W. Duggan, an accredited investor and experienced life sciences executive. Mr. Duggan is a current shareholder of the Company and the former Chairman and CEO of Pharmacyclics Inc. The private placement is expected to yield gross proceeds of $30,040,000.
TherapeuticsMD, Inc. (NASDAQ: TXMD)
Market Cap: $991.236M, current share price: $4.58
TXMD is an innovative healthcare company focused on developing and commercializing products exclusively for women. Earlier this month, the Company announced its scheduled for a total of nine presentations at the 2017 North American Menopause Society annual meeting, in Philadelphia, Pennsylvania, October 11-14. These presentations are related to TX-004HR which is the company's investigational applicator-free vaginal estradiol softgel capsule. This is in development for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.
Genocea Biosciences, Inc. (NASDAQ: GNCA)
Market Cap: $46.164M, current share price: $1.61
Like ENDV, GNCA is working toward creating immunotherapies by targeting T Cell antigens. At the end of last month the Company announced a tactical shift to immuno-oncology with a focus on the development of neoantigen cancer vaccines. This includes its lead candidate, GEN-009, for which it expects to file an Investigational New Drug (IND) application by early 2018.
Exelixis, Inc. (NASDAQ: EXEL)
Market Cap: $9.37B, current share price: $31.78
Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. We discovered our lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies in our efforts to bring them to patients globally. With growing revenues from the three resulting commercialized products - CABOMETYX®, COMETRIQ®, and COTELLIC® - we are reinvesting in our business to maximize the potential of our pipeline, which we intend to supplement with targeted business development activities and internal drug discovery, all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer.
For Full Microcap Speculators Legal Disclaimer Click Here .
DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.
FN Media Group, LLC